Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27845453 | 0.98 | MEN1 (0.33) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL715825 | 0.83 | ALDH1A1 (0.33) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL27862651 | 0.82 | ALDH1A1 (0.33) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL339008 | 0.77 | TP53 (0.43) | ALDH1A1MAPTESR1ESR2TP53 | |
| SCHEMBL2051093 | 0.76 | CA12 (0.41) | MEN1ALDH1A1MAPTKMT2AESR1 | |
| SCHEMBL31299941 | 0.75 | TP53 (0.41) | ALDH1A1MAPTESR1ESR2TP53 | |
| SCHEMBL6382158 | 0.74 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL16334142 | 0.73 | MEN1 (0.33) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL7939919 | 0.73 | MAPT (0.39) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL30122516 | 0.73 | ALDH1A1 (0.39) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5627247-A | COMPOUNDS OF CYCLOPENTADIENE OR INDENE WITH FLUORENE AND GROUP IV METALS | PHILLIPS PETROLEUM COMPANY (US) | 1997-05-06 | — | — | US | claimed |
| US-8357765-B2 | Process for producing catalyst component for addition polymerization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8288490-B2 | Process for producing catalyst component for addition polymerization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120053306-A1 | PROCESS FOR PRODUCING CATALYST COMPONENT FOR ADDITION POLYMERIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120053311-A1 | PROCESS FOR PRODUCING CATALYST COMPONENT FOR ADDITION POLYMERIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053306-A1 | PROCESS FOR PRODUCING CATALYST COMPONENT FOR ADDITION POLYMERIZATION | PPOX, SOD1, AP1M1 | MEN1 2714/4885ALDH1A1 1442/4885MAPT 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.